T Alcindor1, N Beauger. 1. McGill University Departments of Oncology and Medicine, Montreal, QC.
Abstract
OBJECTIVE: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. METHODS OF STUDY SELECTION: We searched the PubMed and PubChem databases by combining the search terms "oxaliplatin" or "platinum" or both, with "clinical trials," "pharmacokinetics," and "pharmacodynamics." DATA EXTRACTION AND SYNTHESIS: Oxaliplatin has a complicated pharmacokinetic profile, with activity against digestive cancers in particular. It has several mechanisms of action, but cancer cells can develop resistance. Real or potential synergism has been observed when oxaliplatin is combined with other cytotoxic agents or molecularly targeted agents. Peripheral neuropathy is a prominent toxic effect. CONCLUSIONS: Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy.
OBJECTIVE: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. METHODS OF STUDY SELECTION: We searched the PubMed and PubChem databases by combining the search terms "oxaliplatin" or "platinum" or both, with "clinical trials," "pharmacokinetics," and "pharmacodynamics." DATA EXTRACTION AND SYNTHESIS: Oxaliplatin has a complicated pharmacokinetic profile, with activity against digestive cancers in particular. It has several mechanisms of action, but cancer cells can develop resistance. Real or potential synergism has been observed when oxaliplatin is combined with other cytotoxic agents or molecularly targeted agents. Peripheral neuropathy is a prominent toxic effect. CONCLUSIONS:Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy.
Entities:
Keywords:
Oxaliplatin; chemotherapy; mechanism of action; targeted therapy
Authors: A Tesniere; F Schlemmer; V Boige; O Kepp; I Martins; F Ghiringhelli; L Aymeric; M Michaud; L Apetoh; L Barault; J Mendiboure; J-P Pignon; V Jooste; P van Endert; M Ducreux; L Zitvogel; F Piard; G Kroemer Journal: Oncogene Date: 2009-11-02 Impact factor: 9.867
Authors: G Cavaletti; G Tredici; M G Petruccioli; E Dondè; P Tredici; P Marmiroli; C Minoia; A Ronchi; M Bayssas; G G Etienne Journal: Eur J Cancer Date: 2001-12 Impact factor: 9.162
Authors: G J Veal; C Dias; L Price; A Parry; J Errington; J Hale; A D Pearson; A V Boddy; D R Newell; M J Tilby Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: Dennis Yi-Shin Kuo; Stephanie V Blank; Paul J Christos; Mimi Kim; Thomas A Caputo; Bhavana Pothuri; Dawn Hershman; Noah Goldman; Percy S Ivy; Carolyn D Runowicz; Franco Muggia; Gary L Goldberg; Mark H Einstein Journal: Gynecol Oncol Date: 2009-11-20 Impact factor: 5.482
Authors: Jim Cassidy; Josep Tabernero; Chris Twelves; René Brunet; Charles Butts; Thierry Conroy; Filippo Debraud; Arie Figer; Johannes Grossmann; Noriaki Sawada; Patrick Schöffski; Alberto Sobrero; Eric Van Cutsem; Eduardo Díaz-Rubio Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: D Arango; A J Wilson; Q Shi; G A Corner; M J Arañes; C Nicholas; M Lesser; J M Mariadason; L H Augenlicht Journal: Br J Cancer Date: 2004-11-29 Impact factor: 7.640
Authors: Nathan B Roberts; Aniket S Wadajkar; Jeffrey A Winkles; Eduardo Davila; Anthony J Kim; Graeme F Woodworth Journal: Oncoimmunology Date: 2016-08-19 Impact factor: 8.110
Authors: Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo Journal: AAPS J Date: 2015-11-17 Impact factor: 4.009